Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

SS-31 / Elamipretide

Elamipretide is a mitochondria-targeting tetrapeptide associated with cardiolipin binding. The SS-31 catalogue label does not establish the approved product formulation. A very small randomized crossover trial in Barth syndrome did not meet its randomized primary endpoints; its extension and later evidence informed accelerated approval based on an intermediate clinical endpoint.

Aliases reviewed
SS-31, MTP-131, Forzinity
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedOne very small randomized crossover trial, with an extension.
Animal/cell
Not rated
Approved medicine
Approved product existsOne U.S. accelerated approval for a specific product in a rare condition.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. Research examines mitochondrial structure, energetics, muscle function, and Barth-syndrome outcomes.

Identity

Elamipretide is a mitochondria-targeting tetrapeptide associated with cardiolipin binding. The SS-31 catalogue label does not establish the approved product formulation.

Biological mechanism or research interest

Research examines mitochondrial structure, energetics, muscle function, and Barth-syndrome outcomes.

Verified approved human uses

FDA granted accelerated approval to Forzinity injection in 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Confirmatory evidence is required; this does not approve an unspecified SS-31 material.

Investigational human evidence

A very small randomized crossover trial in Barth syndrome did not meet its randomized primary endpoints; its extension and later evidence informed accelerated approval based on an intermediate clinical endpoint.

General mitochondrial repair, energy, exercise, anti-aging, or cardioprotection claims exceed the exact approved population and mixed trial results.

Human versus animal or cell evidence

Mitochondrial mechanism findings support biological plausibility but not broad clinical effectiveness.

Limitations and known risks

The approved label and review identify injection-site reactions and serious hypersensitivity-related concerns; generalization to another formulation is unsafe.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.